HOME >> BIOLOGY >> NEWS
Idun develops new drug screen for treatments of stroke, heart attack, and cancer

Key apoptosis reaction adaptable to high throughput screening

KEYSTONE, Colorado, January 22, 2001 - Idun Pharmaceuticals, Inc. described the successful recreation in the lab of a key biological reaction that occurs in human cells and is part of the apoptosis pathway. This assay is being used to help understand the mechanism of apoptosis at the molecular level and to screen new drugs that modulate apoptosis. This development was presented at the Molecular Mechanisms of Apoptosis Meeting in Keystone, Colorado.

In the study, entitled, Reconstitution of Apaf-4/Procaspase-9 Holoenzyme-Mediated Procaspase-3 Activation: Requirement for Caspase-9 Conformational Change or Apaf-1 Association, it was shown that recombinant components of the human apoptosis pathway can be combined in vitro to carry out the activation of one of the key components that triggers programmed cell death.

Developing a key apoptosis reaction in vitro that mimics a natural in vivo reaction has important applications, both for use as a drug screen and as a tool to better understand how apoptosis is regulated, said Dr. Kevin Tomaselli, Vice President, Discovery Research and Co-Founder of Idun Pharmaceuticals. This gives us the ability to screen for drugs in a high throughput format that modulate apoptosis by affecting this specific apoptosis reaction.

Iduns expertise and success in apoptosis encompasses the entire breadth of cutting edge biotechnology, said Steven Mento, Ph.D., President and CEO of Idun Pharmaceuticals. We bring together the disciplines of gene discovery, functional genomics, high throughput screening (HTS), biochemical validation, structural modeling, and targeted drug development and apply them to the discovery and characterization of human apoptosis genes. This includes determining the function of the genes and their role in disease. Based on that, we develop new drugs to treat important human diseases such as cancer, heart attacks and stroke. N
'"/>

Contact: Lora Pike
l.pike@noonanrusso.com
415-677-4455 ext.211
Noonan/Russo Communications
21-Jan-2001


Page: 1 2

Related biology news :

1. Carnegie Mellon neuroscientist develops tool to image brain function at the cellular level
2. Carnegie Mellon U. develops microgel to recover enzymes for manufacturing, research assays
3. Scientists findings may lead to better understanding of how that sleep develops, matures
4. Fox Chase Cancer Center researcher develops new model for studying prions mad cow disease
5. US develops lethal new viruses
6. Brookhaven Lab develops ThraxVac to clean up anthrax
7. Carnegie Mellon develops new process for growing bone
8. Cancer could be caught before it develops
9. St. Jude develops vaccine against potential pandemic influenza virus H5N1 using reverse genetics
10. University of Ulster develops DNA fingerprint techniques to fight bio-terrorism
11. Clothing from Corn: DuPont develops innovative process to create polymer from renewable resources

Post Your Comments:
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: